Avalo Therapeutics, Inc.·4

Jan 3, 4:06 PM ET

Riley Jennifer 4

4 · Avalo Therapeutics, Inc. · Filed Jan 3, 2025

Insider Transaction Report

Form 4
Period: 2025-01-01
Riley Jennifer
Chief Strategy Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-01-01+150,000150,000 total
    Exercise: $7.43Exp: 2035-01-01Common Stock (150,000 underlying)
Footnotes (1)
  • [F1]Twenty-five percent (25%) of the Option Shares vest on January 1, 2026 and the remainder of the Option Shares will vest in equal monthly installments over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date.

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT